At a glance
ClinicalIndex Comparison RecordPhase 2Active· 187 enrolled
Drug / intervention
Elranatamab (PF-06863135)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MAGNETISMM-3 AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 2 STUDY OF ELRANATAMAB (PF-06863135) MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY
In Brief
A Phase 2 clinical trial evaluating Elranatamab (PF-06863135) for Multiple Myeloma. Active but no longer recruiting, targeting 187 participants across 40 sites in 8 countries.
Detailed Summary
The purpose of the study is to evaluate whether single-agent Elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding of Elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesAustralia, Canada, France, Germany, Japan, Poland, Spain, United States
Collaborators--
Timeline
Phase 2Active
2021202220232024202520262027
First PostedDec 2020
Enrollment StartFeb 2021
Primary CompletionJun 2022
TodayJul 2026
Study CompletionDec 2026
First PostedDec 2, 2020
Enrollment StartFeb 2, 2021
Primary CompletionJun 17, 2022
Study CompletionDec 31, 2026
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 5.6 years ago
Interventions
Elranatamab (PF-06863135)drug
BCMA-CD3 bispecific antibody